Publications by authors named "S A Hibbert"

Claim this Profile
E
Exenatide once a week versus placebo as a potential disease-modifying treatment for people with Parkinson's disease in the UK: a phase 3, multicentre, double-blind, parallel-group, randomised, placebo-controlled trial.
Nirosen Vijiaratnam, Christine Girges, Grace Auld, Rachel McComish, Alexa King, Steve Hibbert

Lancet· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Surgical Management and Denosumab for Aneurysmal Bone Cysts of the Spine in an Australian Tertiary Paediatric Centre.
Joel A Vanderniet, Dionysios Tsinas, Christie-Lee Wall, Christian M Girgis, Kevin London, Sally Hibbert

Calcif Tissue Int· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Denosumab for central giant cell granuloma in an Australian tertiary paediatric centre.
Joel A Vanderniet, Christie-Lee Wall, Anna Mullins, Kevin London, Lydia Lim, Sally Hibbert

Bone· June 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Mapping the landscape of Consumer Food Waste.
J Harvey, G Nica-Avram, M Smith, S Hibbert, J Muthuri

Appetite· January 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Exenatide once weekly over 2 years as a potential disease-modifying treatment for Parkinson's disease: protocol for a multicentre, randomised, double blind, parallel group, placebo controlled, phase 3 trial: The 'Exenatide-PD3' study.
Nirosen Vijiaratnam, Christine Girges, Grace Auld, Marisa Chau, Kate Maclagan, Steve Hibbert

BMJ Open· May 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis